Dr Reddy's is currently trading at Rs. 1594.45, up by 50.60 points or 3.28% from its previous closing of Rs. 1543.85 on the BSE.
The scrip opened at Rs. 1540.00 and has touched a high and low of Rs. 1604.00 and Rs. 1540.00 respectively. So far 25,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1604.50 and Rs. 1528.00 respectively. The current market cap of the company is Rs. 27,024 crore.
The promoters holding in the company stood at 25.61% while Institutions and Non-Institutions held 40.85% and 16.73% respectively .
Dr Reddy’s Laboratories has launched Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg), a bioequivalent generic version of REQUIP XL tablets in the US market, following United States Food & Drug Administration (USFDA’s) approval for Dr Reddy’s ANDA for Ropinirole Hydrochloride XR (Extended Release).
The REQUIP XL brand has US sales of approximately $58 million for the most recent twelve months ending March 2012 according to the IMS Health.
Dr Reddy’s Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg) are available in 30 and 90 count bottles sizes, 8 mg and 12 mg are available in 30 count bottle sizes.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1876.90 |
| Dr. Reddys Lab | 1288.50 |
| Cipla | 1339.55 |
| Zydus Lifesciences | 947.20 |
| Lupin | 2244.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: